Horse podoplanin (horPDPN), a type I transmembrane sialoglycoprotein, is expressed on the podocytes of the kidneys, alveolar type I cells of the lungs, and lymphatic endothelial cells. PDPN is a platelet aggregation-inducing factor, and it primarily possesses three platelet aggregation-stimulating (PLAG) domains, that is, PLAG1, PLAG2, and PLAG3, at the N-terminus and several PLAG-like domains. In a previous study, we reported on a mouse anti-horPDPN monoclonal antibody (mAb) clone, PMab-202. Although the effectiveness of PMab-202 in flow cytometry and Western blotting is known, its exact binding epitope remains unknown to date. In this study, enzyme-linked immunosorbent assay and flow cytometry were used to identify the epitope of PMab-202. We found that the critical epitopes of PMab-202 include Lys64, Thr66, and Phe70 of horPDPN. We believe that our findings can be applied in the production of more functional anti-horPDPN mAbs.
Get full access to this article
View all access options for this article.
References
1.
KatoY, FujitaN, KunitaA, SatoS, KanekoM, OsawaM, and TsuruoT: Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem, 2003; 278:51599–51605.
2.
KanekoMK, KatoY, KitanoT, and OsawaM: Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene, 2006; 378:52–57.
3.
Breiteneder-GeleffS, MatsuiK, SoleimanA, MeranerP, PoczewskiH, KaltR, SchaffnerG, and KerjaschkiD: Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol, 1997; 151:1141–1152.
4.
Martin-VillarE, SchollFG, GamalloC, YurritaMM, Munoz-GuerraM, CrucesJ, and QuintanillaM: Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer, 2005; 113:899–910.
5.
KatoY, KanekoMK, KunitaA, ItoH, KameyamaA, OgasawaraS, MatsuuraN, HasegawaY, Suzuki-InoueK, InoueO, OzakiY, and NarimatsuH: Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci, 2008; 99:54–61.
6.
KanekoMK, KunitaA, AbeS, TsujimotoY, FukayamaM, GotoK, SawaY, NishiokaY, and KatoY: Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. Cancer Sci, 2012; 103:1913–1919.
7.
Suzuki-InoueK, KatoY, InoueO, KanekoMK, MishimaK, YatomiY, YamazakiY, NarimatsuH, and OzakiY: Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem, 2007; 282:25993–26001.
8.
NagaeM, Morita-MatsumotoK, KatoM, KanekoMK, KatoY, and YamaguchiY: A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin. Structure, 2014; 22:1711–1721.
9.
Breiteneder-GeleffS, SoleimanA, KowalskiH, HorvatR, AmannG, KriehuberE, DiemK, WeningerW, TschachlerE, AlitaloK, and KerjaschkiD: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium. Am J Pathol, 1999; 154:385–394.
MishimaK, KatoY, KanekoMK, NishikawaR, HiroseT, and MatsutaniM: Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol (Berl), 2006; 111:483–488.
12.
KunitaA, KashimaTG, MorishitaY, FukayamaM, KatoY, TsuruoT, and FujitaN: The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol, 2007; 170:1337–1347.
13.
MishimaK, KatoY, KanekoMK, NakazawaY, KunitaA, FujitaN, TsuruoT, NishikawaR, HiroseT, and MatsutaniM: Podoplanin expression in primary central nervous system germ cell tumors: A useful histological marker for the diagnosis of germinoma. Acta Neuropathol (Berl), 2006; 111:563–568.
14.
KatoY, VaidyanathanG, KanekoMK, MishimaK, SrivastavaN, ChandramohanV, PegramC, KeirST, KuanCT, BignerDD, and ZalutskyMR: Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl Med Biol, 2010; 37:785–794.
15.
KatoY, and KanekoMK: A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep, 2014; 4:5924.
16.
KimuraN, and KimuraI: Podoplanin as a marker for mesothelioma. Pathol Int, 2005; 55:83–86.
17.
AbeS, MoritaY, KanekoMK, HanibuchiM, TsujimotoY, GotoH, KakiuchiS, AonoY, HuangJ, SatoS, KishukuM, TaniguchiY, AzumaM, KawazoeK, SekidoY, YanoS, AkiyamaS, SoneS, MinakuchiK, KatoY, and NishiokaY: A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol, 2013; 190:6239–6249.
18.
Ochoa-AlvarezJA, KrishnanH, PastorinoJG, NevelE, KephartD, LeeJJ, RetzbachEP, ShenY, FatahzadehM, BaredesS, KalyoussefE, HonmaM, AdelsonME, KanekoMK, KatoY, YoungMA, Deluca-RaponeL, ShienbaumAJ, YinK, JensenLD, and GoldbergGS: Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms. Oncotarget, 2015; 6:9045–9060.
19.
SchoppmannSF, JeschB, RieglerMF, MaroskeF, SchwameisK, JomrichG, and BirnerP: Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus. Clin Exp Metastasis, 2013; 30:441–446.
20.
KatoY, KanekoM, SataM, FujitaN, TsuruoT, and OsawaM: Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumor Biol, 2005; 26:195–200.
AriizumiT, OgoseA, KawashimaH, HottaT, LiG, XuY, UmezuH, SugaiM, and EndoN: Expression of podoplanin in human bone and bone tumors: New marker of osteogenic and chondrogenic bone tumors. Pathol Int, 2010; 60:193–202.
23.
KunitaA, KashimaTG, OhazamaA, GrigoriadisAE, and FukayamaM: Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma. Am J Pathol, 2011; 179:1041–1049.
24.
KatoY, SasagawaI, KanekoM, OsawaM, FujitaN, and TsuruoT: Aggrus: A diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene, 2004; 23:8552–8556.
25.
KajiC, TsujimotoY, Kato KanekoM, KatoY, and SawaY: Immunohistochemical examination of novel rat monoclonal antibodies against mouse and human podoplanin. Acta Histochem Cytochem, 2012; 45:227–237.
26.
OkiH, HonmaR, OgasawaraS, FujiiY, LiuX, TakagiM, KanekoMK, and KatoY: Development of sensitive monoclonal antibody PMab-2 against rat podoplanin. Monoclon Antib Immunodiagn Immunother, 2015; 34:396–403.
27.
HonmaR, FujiiY, OgasawaraS, OkiH, LiuX, NakamuraT, KanekoMK, TakagiM, and KatoY: Establishment of a novel monoclonal antibody PMab-32 against rabbit podoplanin. Monoclon Antib Immunodiagn Immunother, 2016; 35:41–47.
28.
HonmaR, KanekoMK, OgasawaraS, FujiiY, KonnaiS, TakagiM, and KatoY: Specific detection of dog podoplanin expressed in renal glomerulus by a novel monoclonal antibody PMab-38 in immunohistochemistry. Monoclon Antib Immunodiagn Immunother, 2016; 35:212–216.
29.
YamadaS, ItaiS, NakamuraT, YanakaM, SaidohN, ChangYW, HandaS, HaradaH, KagawaY, IchiiO, KonnaiS, KanekoMK, and KatoY: PMab-52: Specific and sensitive monoclonal antibody against cat podoplanin for immunohistochemistry. Monoclon Antib Immunodiagn Immunother, 2017; 36:224–230.
KatoY, YamadaS, FurusawaY, ItaiS, NakamuraT, YanakaM, SanoM, HaradaH, FukuiM, and KanekoMK: PMab-213: A monoclonal antibody for immunohistochemical analysis against pig podoplanin. Monoclon Antib Immunodiagn Immunother, 2019; 38:18–24.
32.
KatoY, YamadaS, ItaiS, KobayashiA, KonnaiS, and KanekoMK: Anti-horse podoplanin monoclonal antibody PMab-219 is useful for detecting lymphatic endothelial cells by immunohistochemical analysis. Monoclon Antib Immunodiagn Immunother, 2018; 37:272–274.
33.
FurusawaY, YamadaS, ItaiS, SanoM, NakamuraT, YanakaM, HandaS, MizunoT, MaedaK, FukuiM, HaradaH, KanekoMK, and KatoY: Establishment of monoclonal antibody PMab-202 against horse podoplanin. Monoclon Antib Immunodiagn Immunother, 2018; 37:233–237.
34.
FurusawaY, YamadaS, ItaiS, NakamuraT, YanakaM, SanoM, HaradaH, FukuiM, KanekoMK, and KatoY: PMab-219: A monoclonal antibody for the immunohistochemical analysis of horse podoplanin. Biochem Biophys Rep, 2017; 18:100616.
35.
SekiguchiT, TakemotoA, TakagiS, TakatoriK, SatoS, TakamiM, and FujitaN: Targeting a novel domain in podoplanin for inhibiting plateletmediated tumor metastasis. Oncotarget, 2015; 7:3934–3946.
36.
KanekoMK, NakamuraT, HonmaR, OgasawaraS, FujiiY, AbeS, TakagiM, HaradaH, SuzukiH, NishiokaY, and KatoY: Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med, 2017; 6:382–396.
37.
AndohK, KaiK, MatsumuraT, and MaedaK: Further development of an equine cell line that can be propagated over 100 times. J Equine Sci, 2009; 20:11–14.
38.
YamadaS, ItaiS, NakamuraT, YanakaM, KanekoMK, and KatoY: Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C44Mab-5. Biochem Biophys Rep, 2018; 14:64–68.
